Genetic Medicines to Treat Cardiovascular Disease (N3)
January 1-4, 2027
| Location to be Determined
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Saturday, January 2, 2027
| 8:00–9:00 AM |
Welcome and Keynote Address |
|
| |
Sekar Kathiresan †, Verve Therapeutics
The Human Genome as Teacher and Target: Two Decades of Genomic Discovery to Genomic Medicines |
|
| 9:00–11:15 AM |
New Trailheads: Target Identification for Genetic Medicines in CV Disease |
|
| |
James S. Ware, Imperial College London
Large Scale Genomic Discovery of Causal Mechanisms in Heart Failure |
|
| |
Victoria Parikh †, Stanford University School of Medicine
Genotype-Phenotype Correlation in Inherited Cardiovascular Disease |
|
| |
Rick Dewey, Versant Ventures
Target Selection for Genetic Medicines: Biobanks to Human Proof of Concept |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–12:15 PM |
Panel Discussion 1: Development, Regulatory, Safety, and Ethical Considerations (including long-term and off-target effects of genetic medicines) |
|
| 11:15–1:00 PM |
Poster Setup |
|
| 11:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Emerging Biological Insights Driving the Next Generation of Genetics Medicines for CV Disease |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Mechanisms and Models: From Variation to Validation |
|
| |
Cassady Rupert †, Propria LLC
Modeling Human Cardiac Biology with Multi-Dimensional Engineered Human Heart Tissues |
|
| |
Christine E. Seidman †, Harvard Medical School
Modeling Cardiovascular Disease: Genetics, Cellular Systems, Human Models |
|
| |
Litsa G. Kranias, University of Cincinnati
PLN Cardiomyopathy: From Bedside to Bench and Back to Bedside |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Gene Silencing in Cardiovascular Disease and Promising Avenues |
|
| |
Marianna Fontana †, University College London
CRISPR-Cas9 Gene Editing for TTR Amyloid Cardiomyopathy |
|
| |
Kate A Fitzgerald †, University of Massachusetts Medical School
From RNAi Mechanism to Medicine; the Path to a New Class of Genetic Medicines |
|
| |
Rebecca Ahrens-Nicklas †, Children's Hospital of Philadelphia
In vivo Personalized Genome Editing |
|
| |
Jin Billy Li †, Stanford University
Endogenous RNA Editing in CV Disease: Mechanisms and Therapeutic Applications |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Therapeutic Gene Augmentation Strategies in CV Disease |
|
| |
Roger J. Hajjar †, Mass General Brigham
Engineering the Failing Heart: Innovations in Cardiac Gene Therapy |
|
| |
Annemieke Aartsma-Rus †, Leiden University Medical Center
Exon Skipping to Restore Gene Expression in Muscle Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Homing for Cures: Cardiomyocyte-Directed Delivery Approaches |
|
| |
Luk H. Vandenberghe †, Harvard Medical School
Engineering Viral Delivery Systems |
|
| |
James Dahlman †, Georgia Tech / Emory Medical School
Lipid Nanoparticles: Past, Present, and Future of RNA Delivery |
|
| |
William M Flanagan †, Avidity Biosciences, Inc.
Antibody-Oligo Conjugates for Striated Muscle-Enriched Delivery |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Emerging Translational Strategies in CV Disease |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Products to Patients: Therapeutic Development and Trial Design |
|
| |
Laura F. Michael †, Eli Lilly and Company
Lp(a) - From Genetic Insight to Novel Biology and Breakthrough Therapy |
|
| |
Pushkal Garg †, Alnylam Pharmaceuticals, Inc.
Industry Perspective on Clinical Development of Genetic Therapies |
|
| |
Gene Bukhman †, Brigham and Women's Hospital
Global Health Equity Considerations for New Treatments for CV Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
